Nama's AI scorecard currently rates Alphatec Sell (3.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ATEC's P/E ratio?

Alphatec trades at a trailing price-to-earnings ratio of 29.8.

When does ATEC report earnings?

Alphatec's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.13.

What is the ATEC price target?

The median analyst price target from 14 analysts is $13.00, with a range of $8.00 – $24.00.

Is ATEC Shariah compliant?

Nama's AAOIFI-style screen reads Alphatec as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Alphatec (ATEC)

Healthcare · Medical Devices · NASDAQ

Alphatec (ATEC) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.14B, a trailing price-to-earnings ratio of 29.8 and a free-cash-flow yield of -0.4%. Over the most recent reported fiscal year, revenue grew 24.9%. Nama's AI scorecard rates it Sell, 3.7 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 3.7/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -47.5% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-68.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.14B
Trailing P/E	29.8
Price / book	—
Price / sales	1.4
FCF yield	-0.4%
Dividend yield	—
Gross margin	71.0%
Operating margin	-1.5%
Net margin	-9.7%
Revenue growth (YoY)	+24.9%
Revenue growth (3-yr annual)	+29.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

ATEC earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.13). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.09	$0.09	+0.0%	$221.17M
Q2 2026	Aug 4, 2026	$0.07	$0.07	+0.0%	$213.51M
Q4 2025	Feb 24, 2026	$0.06	$0.04	+50.0%	$212.93M
Q3 2025	Oct 30, 2025	$0.03	-$0.02	+250.0%	$196.50M

ATEC analyst price target

Median target $13.00 from 14 analysts, ranging $8.00 – $24.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live ATEC data on Nama Insights →

ATEC FAQ

Is ATEC a buy?: Nama's AI scorecard currently rates Alphatec Sell (3.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ATEC's P/E ratio?: Alphatec trades at a trailing price-to-earnings ratio of 29.8.
When does ATEC report earnings?: Alphatec's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.13.
What is the ATEC price target?: The median analyst price target from 14 analysts is $13.00, with a range of $8.00 – $24.00.
Is ATEC Shariah compliant?: Nama's AAOIFI-style screen reads Alphatec as Not Shariah Compliant. At least one of the three ratios or the industry test failed.